Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Frontera London

Bristol Myers Squibb logo

BMS’ Opdivo/Yervoy combination fails to shine in melanoma

Combo therapy did not show significant benefit in key patient population

- PMLiVE

FDA clears Alnylam’s second RNAi drug for rare disease

Second drug in the class to be cleared by regulatory authority

- PMLiVE

Signant Health joins the Association of Clinical Research Organizations

Becomes 13th company to join global coalition of research and tech companies

- PMLiVE

Four digital health trends set to reinvent and re-energise pharma

Why AI is set to transform the nature of healthcare

- PMLiVE

New hires at Abbott, Kite and Arrakis Therapeutics

The latest movers in pharma

Early diagnosis underpins NHS cancer strategy

Paul Midgley, Oli Hudson and Sarah Shield, of Wilmington Healthcare, explore how the NHS is tackling cancer in line with the Long-term Plan

Wilmington Healthcare

- PMLiVE

Launch Excellence 2020

In this special pack, we provide a comprehensive outlook of launch excellence. We cover topics ranging from gathering effective insights, to understanding the current landscape, and the importance of pre-launch...

Blue Latitude Health

- PMLiVE

Ashfield appoints new UK head of patient solutions

Stephanie Hill strengthens the commercial team at leading healthcare network

- PMLiVE

OPEN Health reflections on the World Orphan Drug Congress in Barcelona

Having just returned from a very busy but hugely enjoyable few days at congress, I wanted to share our views on the event and key themes that our healthcare communications...

OPEN Health

- PMLiVE

Vertex reveals promising data from first CRISPR-treated patients

Investigational gene therapy has potentially curative effect

- PMLiVE

J&J’s new Darzalex formulation OK’d for use in Europe

Extends use of multiple myeloma therapy even further

- PMLiVE

Myovant preps US filing for relugolix in prostate cancer

Takeda-partnered drug had 97% response rate in advanced prostate cancer

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links